Document Detail

Decreases in parathyroid gland volume after cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism.
MedLine Citation:
PMID:  20413997     Owner:  NLM     Status:  MEDLINE    
BACKGROUND/AIM: Cinacalcet, an allosteric modulator of the calcium-sensing receptor, effectively reduces serum parathyroid hormone (PTH). It was examined whether a regression of parathyroid glands in hemodialysis patients with secondary hyperparathyroidism was induced by cinacalcet treatment.
METHODS: Ultrasonography of the parathyroid glands was performed to examine the changes in the parathyroid gland volumes after cinacalcet treatment in 58 patients.
RESULTS: After cinacalcet treatment, serum calcium, phosphate, alkaline phosphatase, and intact PTH significantly decreased (p < 0.0001). The total volumes of the parathyroid glands were significantly decreased 6 months after cinacalcet treatment (942 +/- 747 vs. 708 +/- 550 mm(3), p < 0.0005). There was a significant positive correlation between the parathyroid gland volumes at the start of cinacalcet treatment and the volume reduction in parathyroid glands (r = 0.716, p < 0.0001). Of the 58 patients, the total parathyroid gland volume was decreased in 42 patients and increased in 16 although the doses of cinacalcet, phosphate binders or vitamin D were not significantly different. In both groups, the intact PTH serum levels were significantly decreased after cinacalcet treatment.
CONCLUSION: Cinacalcet treatment in patients with secondary hyperparathyroidism significantly reduced the total parathyroid gland volume in a short 6-month period. This study suggests that cinacalcet treatment may postpone parathyroidectomy and/or reduce cases.
Mitsuru Ichii; Eiji Ishimura; Senji Okuno; Hidenori Chou; Yoko Kato; Naoki Tsuboniwa; Kyoko Nagasue; Kiyoshi Maekawa; Tomoyuki Yamakawa; Masaaki Inaba; Yoshiki Nishizawa
Related Documents :
15328717 - Hypercalcemia and high serum parathyroid hormone-related protein concentration in a hor...
15708777 - Gsa: behavioral, histological, electrophysiological and neurochemical effects.
12839077 - Fibroblast growth factor 23 concentrations in humoral hypercalcemia of malignancy and h...
1138547 - Pseudohypoparathyroidism. disappearance of the resistance to parathyroid extract during...
6311867 - Corticotropin-releasing factor test in normal subjects and patients with hypothalamic-p...
263717 - Metabolism and excretion of 3h-1,25-(oh)2-vitamin d3 in healthy adults.
Publication Detail:
Type:  Comparative Study; Journal Article     Date:  2010-04-23
Journal Detail:
Title:  Nephron. Clinical practice     Volume:  115     ISSN:  1660-2110     ISO Abbreviation:  Nephron Clin Pract     Publication Date:  2010  
Date Detail:
Created Date:  2010-07-14     Completed Date:  2011-04-14     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  101159763     Medline TA:  Nephron Clin Pract     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  c195-202     Citation Subset:  IM    
Copyright Information:
Copyright 2010 S. Karger AG, Basel.
Department of Endocrinology, Metabolism, and Molecular Medicine, Osaka City University Graduate School of Medicine, Abeno-ku, Osaka, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Follow-Up Studies
Hyperparathyroidism, Secondary / drug therapy*,  etiology*,  ultrasonography
Kidney Failure, Chronic / complications,  drug therapy*,  pathology*
Middle Aged
Naphthalenes / pharmacology,  therapeutic use*
Organ Size / drug effects
Parathyroid Glands / drug effects*,  pathology*,  ultrasonography
Prospective Studies
Renal Dialysis*
Treatment Outcome
Reg. No./Substance:
0/Naphthalenes; UAZ6V7728S/cinacalcet

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Intima-media thickness is associated with inflammation and traditional cardiovascular risk factors i...
Next Document:  Diagnostic value of urinary dysmorphic erythrocytes in clinical practice.